Ingenol mebutate gel (Picato) a novel agent for the treatment of actinic keratoses

P and T

Volumn 39, Issue 1, 2014, Pages 40-46

  Fidler, Brooke ^a   Goldberg, Tamara ^a  

^a LONG ISLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; PHARMADERM; PLACEBO; PROTEIN KINASE C; UNCLASSIFIED DRUG;

ACTINIC KERATOSIS; CELL DEATH; DRUG EFFICACY; ERYTHEMA; HEADACHE; HUMAN; INFLAMMATION; LEUKOCYTE ACTIVATION; NOTE; PHASE 2 CLINICAL TRIAL (TOPIC); RHINOPHARYNGITIS; RISK FACTOR; SKIN CANCER; SKIN DEFECT; SKIN INFECTION; SKIN IRRITATION; SKIN PAIN; SKIN PRURITUS; SKIN SWELLING; SUN EXPOSURE;

EID: 84892509304     PISSN: 10521372     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Note

References (17)

1. Glogau RG. The risk of progression to invasive disease. J Am Acad Dermatol 2000;42(1 Part 2):23-24.
2. Rogers HW, Weinstock MA, Harris AR, et al. Incidence estimate of non-melanoma skin cancer in the United States, 2006. Arch Dermatol 2010;146(3):283-287.
3. American Academy of Dermatology (AAD). Squamous cell carcinoma. Available at: www.aad.org/skin-conditions/ dermatology-a-to-z/squamous-cell-carci-noma. Accessed February 28, 2013.
4. Godar DE, Urbach F, Gasparro FP, van der Leun JC. UV doses of young adults. Photochem Photobiol 2003;77(4):453-457.
5. Salasche SJ. Epidemiology of actinic kera-toses and squamous cell carcinoma. J Am Acad Dermatol 2000;42(1 Part 2):4-7.
6. American Academy of Dermatology (AAD). Actinic keratosis. Available at: www.aad.org/skin-conditions/derma-tology-a-to-z/actinic-keratosis. Accessed February 28, 2013.
7. Kaufmann R, Spelman L, Weightman W, et al. Multicentre intraindividual randomized trial of topical methyl amino-laevulinate-photodynamic therapy vs. cryotherapy for multiple actinic kera-toses on the extremities. Br J Dermatol 2008;158(5):994-999.
8. Hantash BM, Stewart DB, Cooper ZA, et al. Facial resurfacing for nonmelanoma skin cancer prophylaxis. Arch Dermatol 2006;142(8):976-982.
9. Appendino G, Szallasi A. Euphorbium: Modern research on its active principle, resiniferatoxin, revives an ancient medicine. Life Sci 1997;60(10):681-696.
10. Rosen RH, Gupta AK, Tyring SK. Dual mechanism of action of ingenol mebutate gel for topical treatment of actinic kera-toses: Rapid lesion necrosis followed by lesion-specifc immune response. J Am Acad Dermatol 2012;66(3):486-493.
11. Ingenol mebutate (Picato) gel. Parsippa-ny, N.J.: Leo Pharma, Inc.; January 2012.
12. Fallen RS, Gooderham M. Ingenol meb-utate: An introduction. Skin Ther Lett 2012;17(2).
13. Anderson L, Schmieder GJ, Werschler W P, et al. Randomized, double-blind, double-dummy, vehicle-controlled study of ingenol mebutate gel 0.025% and 0.05% for actinic keratosis. J Am Acad Dermatol 2009;60:934-943.
14. Lebwohl M, Swanson N, Anderson LL, et al. Ingenol mebutate gel for actinic ker-atosis. N Engl J Med 2012;366:1010-1019.
15. Red Book Online. Available at: www.thom-sonhc.com. Accessed March 30, 2013.
16. Imiquimod (Aldara) 5% cream, prescribing information. Bristol, Tenn.: 3M/ Graceway; revised October 2010.
17. Diclofenac sodium (Solaraze) gel, prescribing information. Melville, N.Y.: PharmaDerm/Fougera; 2012. n